Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis
Abstract
Abstract Aims The present study aims to determine the effects of sodium‐glucose cotransporter 2 (SGLT‐2) inhibitors on the serum uric acid (SUA) levels of patients with type 2 diabetes mellitus (T2DM) in Asia. Methods PubMed, CENTRAL, Embase and Cochrane Library databases were searched for randomized controlled trials of SGLT‐2 inhibitors in patients with T2DM up to 15 July 2021, without language or date restrictions. Results In total, 19 high‐quality studies (4218 participants) were included in the present network meta‐analysis. All of the included SGLT‐2 inhibitors (empagliflozin, dapagliflozin, canagliflozin, ipragliflozin, luseogliflozin and tofogliflozin) significantly decreased SUA levels compared with those of the control [total standard mean difference –0.965, 95% CI (−1.029, −0.901), p = .000, I 2 = 98.7%] in patients with T2DM. Subgroup analysis and meta‐regression showed that the combined analysis of different inhibitors might lead to heterogeneity of the results. Therefore, among the SGLT‐2 inhibitors, the results of the subsequent network meta‐analysis revealed that luseogliflozin and dapagliflozin ranked the highest in terms of lowering SUA levels among the SGLT‐2 inhibitors. Moreover, the network meta‐analysis declared that luseogliflozin (1 and 10 mg) and dapagliflozin (5 mg) led to a superior reduction in SUA in patients with T2DM. Conclusions SGLT‐2 inhibitors could significantly reduce SUA levels in patients with T2DM, particularly luseogliflozin (1 and 10…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 4,218 participants or records.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.